Long-Term Effectiveness and Safety of Bimekizumab in Patients with Moderate to Severe Hidradenitis Suppurativa Under Real Clinical Practice Conditions: The Importance of Combined Treatment in Hurley III Patients and Potential Factors Associated with Complete Response

Abstract Introduction Hidradenitis suppurativa (HS) is a debilitating, chronic inflammatory skin disease that severely impacts patients’ quality of life. Bimekizumab, the first dual inhibitor of interleukin (IL)-17A and IL-17F, has shown efficacy in phase 3 clinical trials and is currently approved...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Prif Awduron: Miguel Mansilla-Polo, Carmen García-Moronta, Pablo Fernández-Crehuet, Patricia Garbayo-Salmons, Martí Pons-Benavent, Lucía Aguilar-González, David Jiménez-Gallo, Rebeca Alcalá-García, Gemma Martín-Ezquerra, Antonio Martorell, Laura Mahiques-Santos, Fernando Alfageme-Roldán, Begoña Escutia-Muñoz, Antonio Sahuquillo-Torralba, Rafael Fayos-Gregori, Alberto Soto-Moreno, Irene Sánchez-Gutiérrez, Rafael Botella-Estrada, Eva Vilarrasa, Alejandro Molina-Leyva, the Spanish Hidradenitis Suppurativa Group (GEHS)
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Adis, Springer Healthcare 2025-08-01
Cyfres:Dermatology and Therapy
Pynciau:
Hidradenitis suppurativa
Bimekizumab
Real-world evidence
Biologic therapy
Effectiveness
Safety
Mynediad Ar-lein:https://doi.org/10.1007/s13555-025-01521-z
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg